Financial News

Lilly 4Q Revenues Down 9% to $7.3B

COVID-19 antibodies revenue was down 96% in the quarter to $38.0 million and down 10% for the year to $2.0 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly 4Q Revenues: $7.3 billion (-9%) 4Q Earnings: $1.9 billion (+12%) YTD Revenues: $28.5 billion (+1%) YTD Earnings: $6.2 billion (+12%) Comments: Excluding COVID-19 antibodies, revenue in the quarter increased 5% and total worldwide volume increased 13%. Key growth products Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, Retevmo, Emgality, Cyramza, Tyvyt and Olumiant, grew 21% and represented 70% of revenue in the quarter.   COVID-19 antibodies revenue was down 96% in the quarter to $...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters